[SCHEDULE 13G/A] BIO-key International, Inc. SEC Filing
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 359,703 shares of BIO-key International, Inc. common stock, representing 4.99% of the outstanding class. Armistice Capital, a Delaware investment manager, states it exercises shared voting and dispositive power over these shares on behalf of Armistice Capital Master Fund Ltd., the direct holder. Mr. Boyd is identified as the managing member and is reported with the same shared voting and dispositive power.
The filing clarifies the Master Fund retains legal title but disclaims beneficial ownership due to the investment management agreement, and affirms the shares were acquired in the ordinary course of business and not to effect control of the issuer.
Armistice Capital, LLC e Steven Boyd dichiarano la titolarit脿 beneficiaria di 359.703 azioni ordinarie di BIO-key International, Inc., pari al 4,99% della classe in circolazione. Armistice Capital, societ脿 di gestione degli investimenti del Delaware, afferma di esercitare congiuntamente il diritto di voto e il potere dispositive su queste azioni per conto di Armistice Capital Master Fund Ltd., detentore diretto. Il sig. Boyd 猫 indicato come membro amministratore e risulta avere gli stessi poteri congiunti di voto e di disposizione.
Il deposito chiarisce che il Master Fund mantiene la titolarit脿 legale ma rinuncia alla titolarit脿 beneficiaria in virt霉 dell'accordo di gestione degli investimenti, e conferma che le azioni sono state acquisite nell'ordinaria attivit脿 commerciale e non al fine di assumere il controllo dell'emittente.
Armistice Capital, LLC y Steven Boyd informan la propiedad beneficiaria de 359.703 acciones ordinarias de BIO-key International, Inc., que representan el 4,99% de la clase en circulaci贸n. Armistice Capital, un gestor de inversiones de Delaware, declara que ejerce conjuntamente el poder de voto y el poder dispositvo sobre estas acciones en nombre de Armistice Capital Master Fund Ltd., el titular directo. El se帽or Boyd figura como miembro gerente y se informa que posee los mismos poderes compartidos de voto y disposici贸n.
La presentaci贸n aclara que el Master Fund conserva el t铆tulo legal pero renuncia a la propiedad beneficiaria debido al acuerdo de gesti贸n de inversiones, y confirma que las acciones se adquirieron en el curso ordinario del negocio y no para ejercer el control del emisor.
Armistice Capital, LLC鞕� Steven Boyd電� BIO-key International, Inc. 氤错喌欤� 359,703欤�(鞙犿喌 欷戩澑 頃措嫻 欤检嫕鞚� 4.99%)鞐� 雽�頃� 鞁れ鞝� 靻岇湢毳� 氤搓碃頃╇媹雼�. 雿鸽澕鞗柎 韴瀽鞖挫毄靷澑 Armistice Capital鞚� 鞚措煬頃� 欤检嫕鞐� 雽�頃� 鞚橁舶甓� 氚� 觳橂秳甓岇潉 歆侅爲 氤挫湢鞛愳澑 Armistice Capital Master Fund Ltd.毳� 鞙勴暣 瓿惦彊鞙茧 頄夓偓頃滊嫟瓿� 氚濏灆雼堧嫟. Boyd 鞌姅 甏�毽� 氅る矂搿� 旮办灛霅橃柎 鞛堨溂氅� 霃欖澕頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃� 瓴冹溂搿� 氤搓碃霅橃棃鞀惦媹雼�.
鞁犼碃靹滌棎電� 毵堨姢韯� 韼�霌滉皜 氩曥爜 氇呾潣電� 鞙犾頃橂悩 韴瀽鞖挫毄瓿勳暯鞐� 霐半澕 鞁れ鞝� 靻岇湢毳� 攵�鞚疙晿氅�, 欤检嫕鞚� 鞓侅梾靸侅潣 韱奠儊鞝� 瓯半灅瓿检爼鞐愳劀 旆摑霅橃棃瓿� 氚滍枆須岇偓鞚� 歆�氚半ゼ 氇╈爜鞙茧 頃橃 鞎婌晿鞚岇潉 頇曥澑頃橁碃 鞛堨姷雼堧嫟.
Armistice Capital, LLC et Steven Boyd d茅clarent la propri茅t茅 b茅n茅ficiaire de 359 703 actions ordinaires de BIO-key International, Inc., repr茅sentant 4,99 % de la classe en circulation. Armistice Capital, un gestionnaire d'investissements du Delaware, indique qu'il exerce conjointement le droit de vote et le pouvoir de disposition sur ces actions pour le compte d'Armistice Capital Master Fund Ltd., le d茅tenteur direct. M. Boyd est identifi茅 comme membre g茅rant et est d茅clar茅 titulaire des m锚mes pouvoirs partag茅s de vote et de disposition.
Le d茅p么t pr茅cise que le Master Fund conserve le titre juridique mais d茅cline la propri茅t茅 b茅n茅ficiaire en vertu du contrat de gestion d'investissements, et affirme que les actions ont 茅t茅 acquises dans le cours normal des affaires et non dans le but de prendre le contr么le de l'茅metteur.
Armistice Capital, LLC und Steven Boyd melden die wirtschaftliche Eigent眉merschaft an 359.703 Stammaktien von BIO-key International, Inc., was 4,99 % der ausstehenden Aktienklasse entspricht. Armistice Capital, ein in Delaware ans盲ssiger Investmentmanager, gibt an, dass es die Stimm- und Verf眉gungsrechte an diesen Aktien gemeinschaftlich im Namen von Armistice Capital Master Fund Ltd., dem unmittelbaren Inhaber, aus眉bt. Herr Boyd wird als gesch盲ftsf眉hrendes Mitglied genannt und wird mit denselben gemeinsamen Stimm- und Verf眉gungsrechten angegeben.
Die Meldung stellt klar, dass der Master Fund das rechtliche Eigentum beh盲lt, jedoch aufgrund des Investment-Management-Vertrags die wirtschaftliche Eigent眉merschaft bestreitet, und best盲tigt, dass die Aktien im ordentlichen Gesch盲ftsbetrieb erworben wurden und nicht zum Zweck der Kontrolle des Emittenten dienen.
- Clear disclosure of beneficial ownership amounting to 359,703 shares (4.99%)
- Identification of reporting parties including Armistice Capital, LLC and Steven Boyd with addresses and citizenship
- Clarification of voting and dispositive power showing shared voting and shared dispositive power for the reported shares
- Certification that the securities were acquired in the ordinary course of business and not to effect control of the issuer
- None.
Insights
TL;DR: Armistice reports a sub-5% stake (4.99%) in BIO-key, disclosing shared voting and dispositive power via its managed Master Fund.
Armistice Capital and Steven Boyd jointly disclose beneficial ownership of 359,703 shares, equal to 4.99% of BIO-key's common stock. The structure described is typical for an investment manager managing a master fund: the manager reports beneficial control even while the Master Fund is the direct holder and disclaims beneficial ownership due to the investment management agreement. This filing is procedural and consistent with regulatory disclosure obligations for holdings near the 5% threshold, providing clarity on voting and disposition powers without indicating an intent to change control.
TL;DR: Disclosure appropriately distinguishes legal title and managerial control, meeting Schedule 13G/A requirements for sub-5% passive reporting.
The filing identifies Armistice Capital as investment manager and Steven Boyd as managing member, each with shared voting and dispositive power over the reported securities. The Master Fund is named as the direct holder and expressly disclaims beneficial ownership because of the management agreement. Certification language confirms ordinary-course acquisition and no intent to influence issuer control. From a governance standpoint, the filing supplies relevant ownership, voting, and disposition details investors rely on for transparency.
Armistice Capital, LLC e Steven Boyd dichiarano la titolarit脿 beneficiaria di 359.703 azioni ordinarie di BIO-key International, Inc., pari al 4,99% della classe in circolazione. Armistice Capital, societ脿 di gestione degli investimenti del Delaware, afferma di esercitare congiuntamente il diritto di voto e il potere dispositive su queste azioni per conto di Armistice Capital Master Fund Ltd., detentore diretto. Il sig. Boyd 猫 indicato come membro amministratore e risulta avere gli stessi poteri congiunti di voto e di disposizione.
Il deposito chiarisce che il Master Fund mantiene la titolarit脿 legale ma rinuncia alla titolarit脿 beneficiaria in virt霉 dell'accordo di gestione degli investimenti, e conferma che le azioni sono state acquisite nell'ordinaria attivit脿 commerciale e non al fine di assumere il controllo dell'emittente.
Armistice Capital, LLC y Steven Boyd informan la propiedad beneficiaria de 359.703 acciones ordinarias de BIO-key International, Inc., que representan el 4,99% de la clase en circulaci贸n. Armistice Capital, un gestor de inversiones de Delaware, declara que ejerce conjuntamente el poder de voto y el poder dispositvo sobre estas acciones en nombre de Armistice Capital Master Fund Ltd., el titular directo. El se帽or Boyd figura como miembro gerente y se informa que posee los mismos poderes compartidos de voto y disposici贸n.
La presentaci贸n aclara que el Master Fund conserva el t铆tulo legal pero renuncia a la propiedad beneficiaria debido al acuerdo de gesti贸n de inversiones, y confirma que las acciones se adquirieron en el curso ordinario del negocio y no para ejercer el control del emisor.
Armistice Capital, LLC鞕� Steven Boyd電� BIO-key International, Inc. 氤错喌欤� 359,703欤�(鞙犿喌 欷戩澑 頃措嫻 欤检嫕鞚� 4.99%)鞐� 雽�頃� 鞁れ鞝� 靻岇湢毳� 氤搓碃頃╇媹雼�. 雿鸽澕鞗柎 韴瀽鞖挫毄靷澑 Armistice Capital鞚� 鞚措煬頃� 欤检嫕鞐� 雽�頃� 鞚橁舶甓� 氚� 觳橂秳甓岇潉 歆侅爲 氤挫湢鞛愳澑 Armistice Capital Master Fund Ltd.毳� 鞙勴暣 瓿惦彊鞙茧 頄夓偓頃滊嫟瓿� 氚濏灆雼堧嫟. Boyd 鞌姅 甏�毽� 氅る矂搿� 旮办灛霅橃柎 鞛堨溂氅� 霃欖澕頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃� 瓴冹溂搿� 氤搓碃霅橃棃鞀惦媹雼�.
鞁犼碃靹滌棎電� 毵堨姢韯� 韼�霌滉皜 氩曥爜 氇呾潣電� 鞙犾頃橂悩 韴瀽鞖挫毄瓿勳暯鞐� 霐半澕 鞁れ鞝� 靻岇湢毳� 攵�鞚疙晿氅�, 欤检嫕鞚� 鞓侅梾靸侅潣 韱奠儊鞝� 瓯半灅瓿检爼鞐愳劀 旆摑霅橃棃瓿� 氚滍枆須岇偓鞚� 歆�氚半ゼ 氇╈爜鞙茧 頃橃 鞎婌晿鞚岇潉 頇曥澑頃橁碃 鞛堨姷雼堧嫟.
Armistice Capital, LLC et Steven Boyd d茅clarent la propri茅t茅 b茅n茅ficiaire de 359 703 actions ordinaires de BIO-key International, Inc., repr茅sentant 4,99 % de la classe en circulation. Armistice Capital, un gestionnaire d'investissements du Delaware, indique qu'il exerce conjointement le droit de vote et le pouvoir de disposition sur ces actions pour le compte d'Armistice Capital Master Fund Ltd., le d茅tenteur direct. M. Boyd est identifi茅 comme membre g茅rant et est d茅clar茅 titulaire des m锚mes pouvoirs partag茅s de vote et de disposition.
Le d茅p么t pr茅cise que le Master Fund conserve le titre juridique mais d茅cline la propri茅t茅 b茅n茅ficiaire en vertu du contrat de gestion d'investissements, et affirme que les actions ont 茅t茅 acquises dans le cours normal des affaires et non dans le but de prendre le contr么le de l'茅metteur.
Armistice Capital, LLC und Steven Boyd melden die wirtschaftliche Eigent眉merschaft an 359.703 Stammaktien von BIO-key International, Inc., was 4,99 % der ausstehenden Aktienklasse entspricht. Armistice Capital, ein in Delaware ans盲ssiger Investmentmanager, gibt an, dass es die Stimm- und Verf眉gungsrechte an diesen Aktien gemeinschaftlich im Namen von Armistice Capital Master Fund Ltd., dem unmittelbaren Inhaber, aus眉bt. Herr Boyd wird als gesch盲ftsf眉hrendes Mitglied genannt und wird mit denselben gemeinsamen Stimm- und Verf眉gungsrechten angegeben.
Die Meldung stellt klar, dass der Master Fund das rechtliche Eigentum beh盲lt, jedoch aufgrund des Investment-Management-Vertrags die wirtschaftliche Eigent眉merschaft bestreitet, und best盲tigt, dass die Aktien im ordentlichen Gesch盲ftsbetrieb erworben wurden und nicht zum Zweck der Kontrolle des Emittenten dienen.
FAQ
What stake in BIO-key (BKYI) did Armistice Capital disclose?
Who holds voting and disposition power over the reported BIO-key shares?
Is the Master Fund the direct holder of the BIO-key shares?
Did the filing state intent to influence control of BIO-key?
When was the Schedule 13G/A signed?
